A patient experiencing panic attacks after a recent breakup was prescribed clonazepam 1 mg in the emergency department; what is the usual dosing for panic attacks and how should clonazepam be tapered off safely?

Clonazepam Dosing and Tapering for Panic Attacks

For acute panic attacks from situational stress like a breakup, clonazepam 1 mg from the ED should be used only as a short-term bridge (days to 1-2 weeks maximum) while initiating evidence-based psychotherapy (CBT) and/or SSRIs, followed by a gradual taper of 25% dose reduction every 1-2 weeks to minimize withdrawal risks.

Standard Dosing for Panic Disorder

The FDA-approved dosing for clonazepam in panic disorder demonstrates that 1 mg daily is the minimum effective dose 1. Clinical trials show:

• Initial dosing: Start at 0.5 mg daily, titrate upward over 3 weeks
• Therapeutic range: 1-2 mg daily provides optimal balance of efficacy and tolerability 2
• Maximum dose: Up to 4 mg daily, though higher doses (3-4 mg) increase side effects without additional benefit 2
• Mean effective dose in trials: 2.3 mg daily 1

However, this patient's situation differs critically from chronic panic disorder—he has situational panic attacks from acute psychosocial stress (breakup), not a panic disorder diagnosis requiring long-term benzodiazepine therapy.

Critical Context: This is NOT Standard Panic Disorder Treatment

Benzodiazepines should not be first-line for panic disorder, and especially not for situational anxiety. The evidence strongly supports:

• First-line treatment: SSRIs combined with CBT 3
• Benzodiazepines as adjunct only: For acute symptom relief while waiting for SSRI onset (2-4 weeks) 4
• Short-term use: Days to weeks, not months or years

The CDC guidelines emphasize that benzodiazepines carry significant risks including dependence, withdrawal seizures, and death—particularly when combined with other CNS depressants 5. Abrupt discontinuation can cause rebound anxiety, hallucinations, seizures, delirium tremens, and rarely death 5.

Safe Tapering Protocol

The safest approach uses a 25% dose reduction every 1-2 weeks 5. For this patient on 1 mg:

Week-by-Week Taper Schedule:

1. Weeks 1-2: 1 mg daily (current dose)
2. Weeks 3-4: 0.75 mg daily (25% reduction)
3. Weeks 5-6: 0.5 mg daily (33% reduction from 0.75 mg)
4. Weeks 7-8: 0.25 mg daily (50% reduction from 0.5 mg)
5. Week 9+: Discontinue

Alternative slower taper (if withdrawal symptoms emerge): Reduce by 0.25 mg every 2 weeks 6:

• Weeks 1-2: 1 mg
• Weeks 3-4: 0.75 mg
• Weeks 5-6: 0.5 mg
• Weeks 7-8: 0.25 mg
• Week 9+: Discontinue

Key Tapering Principles:

• Monitor for withdrawal symptoms: Anxiety, insomnia, tremor, sweating, tachycardia, nausea, headache 6
• Slow the taper if symptoms emerge: The rate should be individualized based on tolerance 5
• Very small final doses may be needed: Some patients require doses as low as 0.2 mg or less for the final step 7
• Hyperbolic tapering is superior: Proportionate reductions (25% of current dose) produce more consistent pharmacological changes than linear reductions 7

Concurrent Treatment Strategy

While tapering clonazepam, immediately initiate:

1. Evidence-based psychotherapy: CBT is first-line for panic/anxiety 5, 3

2. Consider SSRI: If symptoms persist beyond acute stress reaction

   • Sertraline, citalopram, or escitalopram are good first choices
   • Takes 2-4 weeks for effect
   • Can be combined with CBT for superior outcomes 3

3. Non-pharmacologic interventions:

   • Breathing techniques
   • Stress management
   • Sleep hygiene
   • Avoid alcohol and stimulants

Critical Safety Warnings

Avoid concurrent opioids: The combination quadruples overdose death risk 5. If the patient requires opioids for any reason, this becomes a medical emergency requiring specialist consultation.

Never abruptly stop: Benzodiazepine withdrawal can be life-threatening, unlike opioid withdrawal 5. Seizures can occur with abrupt discontinuation.

Watch for dependence: Even at therapeutic doses for short periods, physical dependence can develop 1. The patient should be counseled that:

• Tolerance may develop
• Withdrawal symptoms are expected during taper
• This does not mean addiction, but rather physiological adaptation

Follow-Up Schedule

• Weekly contact during taper (phone, telehealth, or in-person) 8
• Assess withdrawal symptoms at each contact
• Monitor for return of panic symptoms
• Adjust taper speed based on patient tolerance
• Screen for depression and substance use 5

When to Refer

Consider psychiatry referral if:

• Unable to taper despite slow reduction
• Severe withdrawal symptoms emerge
• Panic symptoms worsen significantly
• Co-occurring substance use disorder
• Suicidal ideation develops 1

The goal is complete discontinuation within 2-3 months maximum, with transition to evidence-based long-term treatments (psychotherapy ± SSRI) that address the underlying anxiety without dependence risk.